Heidenheim A Paul, Muirhead Norman, Moist Louise, Lindsay Robert M
Optimal Dialysis Research Unit, London Health Sciences Center, London, Ontario, Canada.
Am J Kidney Dis. 2003 Jul;42(1 Suppl):36-41. doi: 10.1016/s0272-6386(03)00536-5.
Studies have shown improved quality of life for hemodialysis (HD) patients after changing from conventional thrice-weekly HD treatment to more frequent HD.
In the London Daily/Nocturnal Hemodialysis Study, 23 patients (11 patients, short daily HD; 12 patients, long nocturnal HD) were compared with 22 conventional thrice-weekly HD patients serving as controls. All patients completed 3 sets of quality-of-life assessment tools: (1) a locally developed renal disease-specific questionnaire that assessed dialysis symptoms, uremic symptoms, psychosocial stress, and social-leisure activity; (2) the generic Medical Outcomes Survey 36-Item Short Form (SF-36); and (3) the global Health Utilities Index (HUI). As a supplement to the HUI, a subset of patients was asked to complete the Time Trade-Off assessment.
Overall, the reduction in symptoms shows better fluid management because quotidian HD patients reported experiencing fewer and less severe cramping during dialysis, fewer headaches, less hypotension, fewer episodes of dizziness, decreased fluid restrictions, fewer blood pressure problems, decreased interdialytic weight gains, fewer episodes of shortness of breath, and a reduction in the sensation of easily feeling cold. HUI results showed that quotidian HD patients maintained functionality throughout the study period, whereas control patients showed a significant loss. Given the choice, all patients chose to remain on quotidian HD therapy after switching from conventional HD therapy. The Time Trade-Off analysis indicated that study patients were willing to trade far less time on quotidian HD therapy and much more time on conventional HD therapy in exchange for "perfect" health.
As more studies focus on improved patient outcomes and appropriate funding mechanisms are established, more frequent home HD treatment should become a standard treatment option for patients with end-stage renal disease.
研究表明,血液透析(HD)患者从传统的每周三次HD治疗改为更频繁的HD治疗后,生活质量得到改善。
在伦敦每日/夜间血液透析研究中,将23例患者(11例每日短程HD患者;12例夜间长程HD患者)与22例作为对照的传统每周三次HD患者进行比较。所有患者均完成3套生活质量评估工具:(1)一份本地开发的肾脏疾病特异性问卷,评估透析症状、尿毒症症状、心理社会压力和社交休闲活动;(2)通用的医学结局研究简明健康调查问卷(SF-36);(3)全球健康效用指数(HUI)。作为对HUI的补充,部分患者被要求完成时间权衡评估。
总体而言,症状减轻表明液体管理更佳,因为每日HD患者报告透析期间抽筋次数更少、程度更轻,头痛更少,低血压更少,头晕发作次数更少,液体限制减少,血压问题减少,透析间期体重增加减少,呼吸急促发作次数减少,以及易感冒的感觉减轻。HUI结果显示,每日HD患者在整个研究期间保持了功能,而对照患者则出现了显著丧失。如果可以选择,所有患者在从传统HD治疗转换后都选择继续接受每日HD治疗。时间权衡分析表明,研究患者愿意用少得多的时间接受每日HD治疗,而用多得多的时间接受传统HD治疗来换取“完美”健康。
随着更多研究关注改善患者结局并建立适当的资金机制,更频繁的家庭HD治疗应成为终末期肾病患者的标准治疗选择。